HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CFSAN Simplifies Guidance For Secure Cosmetic Manufacturing With “Tool”

This article was originally published in The Rose Sheet

Executive Summary

FDA's Center for Food Safety and Applied Nutrition has updated its "Security Preventive Measures Guidance" for cosmetic processors and transporters with a self-assessment tool that helps to simplify the information, the agency announces

You may also be interested in...

Global Supply Chain Concern Prompts FDA Guidance On Glycerin Testing

Manufacturing facilities should test all lots of glycerin they receive for diethylene glycol (DEG) content to avoid product contamination, FDA says in a guidance reflecting growing concern about vulnerabilities in the global supply chain

CTFA on security

"It is very important to emphasize" FDA's draft security guidance for cosmetics processors and transporters should not be considered minimum standards that every cosmetics company must meet, Cosmetic, Toiletry and Fragrance Association states in May 20 comments to the agency. "Because of the diversity of the industry, all of the guidance may not be applicable to every company, CTFA adds. Association claims FDA's guidelines are "remarkably consistent" with its own Product Security and Tampering Incident guidelines and says it supports efforts by FDA to encourage regulated industries to be attentive to product security. FDA's draft guidelines, released in March, recommend random plant security inspections (1"The Rose Sheet" March 24, 2003, p. 6)...

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts